STEVENSON, Md., Jan. 03, 2018 -- The securities litigation law firm of Brower Piven, A Professional Corporation, announces that a class action lawsuit has been commenced in the United States District Court for the Central District of California on behalf of purchasers of Capitala Finance Corp. (Nasdaq:CPTA) (“Capitala” or the “Company”) securities during the period between January 4, 2016 through August 7, 2017, inclusive (the “Class Period”). Investors who wish to become proactively involved in the litigation have until February 26, 2018 to seek appointment as lead plaintiff.
If you wish to choose counsel to represent you and the class, you must apply to be appointed lead plaintiff and be selected by the Court. The lead plaintiff will direct the litigation and participate in important decisions including whether to accept a settlement for the class in the action. The lead plaintiff will be selected from among applicants claiming the largest loss from investment in Capitala securities during the Class Period. Members of the class will be represented by the lead plaintiff and counsel chosen by the lead plaintiff. No class has yet been certified in the above action.
The complaint accuses the defendants of violations of the Securities Exchange Act of 1934 by virtue of the defendants’ failure to disclose during the Class Period that Capitala had been losing professional talent in both underwriting and portfolio management due to the waiving of its incentive fee which impacted the quality of the Company’s investment portfolio.
According to the complaint, following an August 7, 2017 announcement that six of the Company’s investments were on non-accrual status, and an August 8, 2017 announcement that Capitala had been losing professional talent, which gave rise to a rising number of nonaccrual investments, the value of Capitala shares declined significantly.
If you have suffered a loss in excess of $100,000 from investment in Capitala securities purchased on or after January 4, 2016 and held through the revelation of negative information during and/or at the end of the Class Period and would like to learn more about this lawsuit and your ability to participate as a lead plaintiff, without cost or obligation to you, please contact Brower Piven either by email at [email protected] or by telephone at (410) 415-6616.
Attorneys at Brower Piven have extensive experience in litigating securities and other class action cases and have been advocating for the rights of shareholders since the 1980s. If you choose to retain counsel, you may retain Brower Piven without financial obligation or cost to you, or you may retain other counsel of your choice. You need take no action at this time to be a member of the class.
CONTACT: Charles J. Piven
Brower Piven, A Professional Corporation
1925 Old Valley Road
Stevenson, Maryland 21153
Telephone: 410-415-6616
[email protected]


Russia Signals Further Restrictions on Telegram Amid Ongoing Regulatory Disputes
Ancora Holdings Builds $200M Stake in Warner Bros Discovery, Targets Netflix Asset Sale Plan
CBA Shares Surge After Record Half-Year Profit as Rate Outlook Improves
xAI Co-Founder Jimmy Ba Departs as Elon Musk’s AI Startup Faces Turbulence
Cloudflare Forecasts Strong Revenue Growth as AI Fuels Cloud Services Demand
Spirit Airlines Seeks Court Approval to Auction 20 Airbus A320/A321 Aircraft Amid Bankruptcy
U.S. Commerce Department Reaches $252 Million Settlement With Applied Materials Over China Exports
AST SpaceMobile Joins MSCI ACWI Index as Largest New Addition, Boosting Market Visibility
Samsung Electronics Sees Sustained AI-Driven Demand for Memory Chips Into Next Year
Instagram CEO Defends Platform in Youth Mental Health Lawsuit Over Social Media Addiction Claims
FTC Questions Apple News Over Alleged Bias Against Conservative Media
How Marco Pharma International Preserves German Homeopathic Traditions in America
AbbVie Sues HHS Over Medicare Price Controls on Botox Under Inflation Reduction Act
ANZ Shares Hit Record High After Strong Q1 Profit and Cost-Cutting Gains
SMIC Shares Slide Despite Strong AI-Driven Earnings as Margin Pressure Looms
More U.S. Investors Join Arbitration Against South Korea Over Coupang Dispute
Novocure Stock Surges 30% After FDA Approves Optune Pax for Pancreatic Cancer Treatment 



